bis(2- ((4- ((4'- (2- hydroxyethoxy)- 2'- methyl(1,1'- biphenyl)- 3- yl)methoxy)phenyl)methyl)- 3,5- dioxo- 1,2,4- oxadiazolidine)

a GPR40 agonist; structure in first source

Also Known As:

AS2034178; bis(2-((4-((4'-(2-hydroxyethoxy)-2'-methyl(1,1'-biphenyl)-3-yl)methoxy)phenyl)methyl)-3,5-dioxo-1,2,4-oxadiazolidin-4-ide)

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

1.	Colitis 06/01/2019 - "Furthermore, AS2034178 significantly promoted the healing of DSS-induced colitis. " 06/01/2019 - "In the present study, we investigated the ameliorative effect of GPR40 activation in a dextran sulfate sodium (DSS)-induced murine colitis model using a specific GPR40 agonist, AS2034178. "
2.	Neoplasms (Cancer) 06/24/2023 - "Using the selective FFA1 agonist AS2034178 and the selective FFA1 antagonist GW1100, we examined the role of FFA1 in modulating cell migration, invasion, proliferation and tumor growth and assessed the FFA1-associated intracellular signaling mechanisms via immunoblotting. "
3.	Insulin Resistance 09/01/2013 - "Repeat administration of AS2034178 enhanced insulin sensitivity in an insulin tolerance test and a euglycemic-hyperinsulinemic clamp test. "
4.	Type 2 Diabetes Mellitus (MODY) 09/01/2013 - "In conclusion, AS2034178 and other GPR40 agonists may become useful therapeutics in the treatment of type 2 diabetes mellitus. "

1.	Therapeutics